QuantRx Biomedical Corporation
QTXB · OTC
9/30/2022 | 6/30/2022 | 3/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | -0.04 | 0.16 | 0.00 |
| FCF Yield | -0.84% | -5.91% | -0.01% | -1.92% |
| EV / EBITDA | -451.61 | -118.08 | -873.29 | -520.77 |
| Quality | ||||
| ROIC | 65.35% | 27.75% | 45.79% | 153.72% |
| Gross Margin | 0.00% | 0.00% | 0.00% | 0.00% |
| Cash Conversion Ratio | 0.06 | 0.36 | 0.00 | 0.25 |
| Growth | ||||
| Revenue 3-Year CAGR | -100.00% | -100.00% | -100.00% | -100.00% |
| Free Cash Flow Growth | 87.15% | -97,480.00% | 99.80% | -125.22% |
| Safety | ||||
| Net Debt / EBITDA | -389.74 | -99.66 | -744.53 | -400.87 |
| Interest Coverage | -0.13 | -0.50 | -0.07 | -0.12 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | 0.00 | 0.00 | 0.00 |